Valuation: Adocia

Market Cap 8.09Cr 9.36Cr 7.56Cr 6.93Cr 13Cr 890.37Cr 13Cr 89Cr 35Cr 446.28Cr 35Cr 34Cr 1.48TCr P/E 2026 *
-755x
P/E 2027 * 5.98x
Enterprise Value 5.11Cr 5.91Cr 4.77Cr 4.38Cr 8.23Cr 562.02Cr 8.36Cr 56Cr 22Cr 281.7Cr 22Cr 22Cr 931.28Cr EV / Sales 2026 *
20.3x
EV / Sales 2027 * 3.14x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 80 24/02/2012
Director/Board Member 58 18/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.36Cr
+8.49%+20.55%+70.77%+110.32% 6.81TCr
+1.25%+2.44%+34.27%+70.43% 5.52TCr
-1.09%+32.96%+19.67%+494.56% 2.86TCr
+10.83%+18.38%+56.20%+6.03% 2.4TCr
+2.72%+3.41%-16.11%-7.96% 2.35TCr
+6.50%+7.56%+44.65%-21.73% 1.84TCr
+6.20%+11.51%+33.87%+693.38% 1.64TCr
-3.88%+16.98%+199.30%+359.77% 1.58TCr
+3.58%+1.96%+43.35%+163.76% 1.34TCr
Average +3.46%+11.68%+54.00%+207.62% 2.93TCr
Weighted average by Cap. +4.36%+13.10%+50.69%+168.47%

Financials

2026 *2027 *
Net sales 25.22L 29.15L 23.55L 21.6L 40.63L 28Cr 41.27L 2.76Cr 1.08Cr 14Cr 1.09Cr 1.07Cr 46Cr 3.54Cr 4.09Cr 3.31Cr 3.03Cr 5.7Cr 389.49Cr 5.79Cr 39Cr 15Cr 195.22Cr 15Cr 15Cr 645.39Cr
Net income -43.17L -49.91L -40.32L -36.98L -69.56L -47Cr -70.67L -4.73Cr -1.86Cr -24Cr -1.87Cr -1.83Cr -79Cr -4.43Cr -5.12Cr -4.14Cr -3.8Cr -7.14Cr -487.71Cr -7.26Cr -49Cr -19Cr -244.45Cr -19Cr -19Cr -808.15Cr
Net Debt -2.98Cr -3.45Cr -2.79Cr -2.56Cr -4.81Cr -328.35Cr -4.89Cr -33Cr -13Cr -164.58Cr -13Cr -13Cr -544.09Cr 3.02Cr 3.49Cr 2.82Cr 2.59Cr 4.86Cr 332.01Cr 4.94Cr 33Cr 13Cr 166.41Cr 13Cr 13Cr 550.16Cr
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-